ReviewTrends in biotechnology2003
Biological applications of protein transduction technology.
Review in Trends in biotechnology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells.The Journal of biological chemistry · 2024Article
- Protective effects of cell permeable Tat-PIM2 protein on oxidative stress induced dopaminergic neuronal cell death.Heliyon · 2023Article
- A micellized bone morphogenetic protein-7 prodrug ameliorates liver fibrosis by suppressing transforming growth factor-American journal of cancer research · 2022Article
- Cell cycle dependence of apoptosis photo-triggered using peptide-photosensitizer conjugate.Scientific reports · 2020Article
- Micellized Protein Transduction Domain-Bone Morphogenetic Protein-7 Efficiently Blocks Renal Fibrosis Via Inhibition of Transforming Growth Factor-Beta-Mediated Epithelial-Mesenchymal Transition.Frontiers in pharmacology · 2020Article
- Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson's disease models.Experimental & molecular medicine · 2018Article
- TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells.Journal of cellular and molecular medicine · 2018Article
- The FKBP51 Glucocorticoid Receptor Co-Chaperone: Regulation, Function, and Implications in Health and Disease.International journal of molecular sciences · 2017Review
- Article
- Article
- Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.Molecular medicine (Cambridge, Mass.) · 2013Article
- Suppression of TLR signaling by targeting TIR domain-containing proteins.Current protein & peptide science · 2012Review
- Molecular mechanism of cytotoxicity induced by Hsp90-targeted Antp-TPR hybrid peptide in glioblastoma cells.Molecular cancer · 2012Article
- Construction of recombinant proteins for reprogramming of endangered Luxi cattle fibroblast cells.Molecular biology reports · 2012Article
- MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism.The Journal of biological chemistry · 2012Article
- Proteins reprogramming: present and future.TheScientificWorldJournal · 2012Review
- Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent.Journal of translational medicine · 2011Article
- A new method for direct detection of the sites of actin polymerization in intact cells and its application to differentiated vascular smooth muscle.American journal of physiology. Cell physiology · 2010Article
- Article
- Polymeric linear Peptide chimeric vaccine-induced antimalaria immunity is associated with enhanced in vitro antigen loading.Infection and immunity · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The impermeable nature of the cell membrane to peptides, proteins, DNA and oligonucleotides limits the therapeutic potential of these biological agents. However, the recent discovery of short cationic peptides that cross the plasma membrane efficiently is opening up new possibilities for the intracellular delivery of such agents. These peptides are commonly referred to as protein transduction domains (PTDs) and are successfully used to transport heterologous proteins, peptides and other types of cargo into cells. Several recent reports have used the membrane transducing technology in vivo to deliver biologically active cargo into various tissues. This review discusses the structure of the most commonly used PTDs and how their ability to transduce membranes is used to regulate biological functions. It also considers future directions and the potential of this technology to move from the laboratory into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.